Genetic markers of pharmacokinetic features in patients with a severe outcome of schizophrenia, resistant to antipsychotic therapy
https://doi.org/10.29235/1818-9857-2023-07-78-83
Abstract
The article analysed the relationships between genetic factors and resistance of patients with a severe outcome of schizophrenia to ongoing drug treatment, which is necessary to understand the reasons for the formation of such an endophenotype.
Keywords
шизофрения,
исходы лечения,
антипсихотики,
фармакогенетика,
полиморфизм генов,
гены CYP2D6,
MDR1,
MTHFR
About the Authors
V. Obiedkov
Белорусский государственный медицинский университет
Belarus
Belarus
Viktor Obiedkov
I. Goloenko
Институт генетики и цитологии НАН Беларуси
Belarus
Belarus
Inessa Goloenko
O. Bokut
Институт биоорганической химии НАН Беларуси
Belarus
Belarus
Olga Bokut
T. Dokukina
РНПЦ психического здоровья
Belarus
Belarus
Tatiana Dokukina
T. Golubeva
РНПЦ психического здоровья
Belarus
Belarus
Tatiana Golubeva
L. Tishkevich
РНПЦ психического здоровья
Belarus
Belarus
Larisa Tishkevich
A. Khodzhaev
РНПЦ психического здоровья
Belarus
Belarus
Alexander Khodzhaev
References
1. Volavka J. Very long-term outcome of schizophrenia / J. Volavka, J. Vevera // Int. J. Clin. Pract, 2018. Vol. 72 (7).
2. Davis L. Economics and schizophrenia: the real cost / L. Davis, M. Drummond // Br. J. Psychiatry. 1994. Vol. 25. P. 18–21.
3. Characteristics of very poor outcome schizophrenia / R. Keefe [et al.] // American Journal of Psychiatry. 1987. Vol. 144 (889). P. 895.
4. Kraepelinian schizophrenia: A subgroup of schizophrenia? / R. Keefe [et al.] // Psychopharmacological Bulletin. 1988. Vol. 24 (56). Р. 61.
5. Premorbidsociosexual functioning and long-term outcome in schizophrenia / R. Keefe [et al.] // American Journal of Psychiatry. 1989. Vol. 146 (206) Р. 211.
6. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project / G. Blokland [et al.] // Schizophrenia Research. 2018. Vol. 195 (306). Р. 317.
7. Gaebel W. New concepts for predicting the outcome in neuroleptic treatment / W. Gaebel // Eur. Arch. Psychiatry Clin. Neurosci. 2009. Vol. 259 (1). P. 42.
8. Degenhardt F. Update on the genetic architecture of schizophrenia / F. Degenhardt // Medizinische genetic. 2020. Vol. 32(1). P. 19–24.
9. De Leon J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness / J. Leon [et al.] // J. ClinPsychopharmacol. 2005. Vol. 25 (5). P. 448–456.
10. De Luca V. MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis / V. DeLuca [et al.] // Schizophr. Res. 2009. Vol. 110 (1–3). P. 200–201.
11. Foster A. Pharmacogenetics and schizophrenia / A. Foster, D. D. Miller, P. F. Buckley // Psychiatric Clinics of North America. 2007. Vol. 30 (3). P. 417–435.
12. Patsopoulos N. A. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis / N. A. Patsopoulos, E. E. Ntzani, E. Zintzaras, J. P. Ioannidis // Pharmacogenet. Genomics. 2005. Vol. 15 (3). P. 151–158.
13. D₂-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D / E. Daskalopoulos [et al.] // Mol. Pharmacol. 2012. Vol. 82 (4). P. 668–678.
14. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6 / S. Thümmler [et al.] // Front Psychiatry. 2018. Vol. 24 (9). P. 2.
15. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study / C. Kobylecki [et al.] // Ther Drug Monit. 2008. Vol. 30 3). P. 265–270.
16. Methylenetetrahydrofolate reductase gene variants and antipsychotic–induced weight gain and metabolic disturbances / A. Kao [et al.] // J. Psychiatr. Res. 2014. Vol. 54. P. 36–42.
17. The influence of 5–HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients / R. Kuzman [et al.] // Psychiatry Res. 2008. Vol. 160 (3). P. 308–315.
18. Youssef D. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids / D. Youssef, T. Attia, A. El-Shal, F. Abduelometty // Gene. 2013. Vol. 10 (530). P. 201–207.
Review
For citations:
Obiedkov V., Goloenko I., Bokut O., Dokukina T., Golubeva T., Tishkevich L., Khodzhaev A. Genetic markers of pharmacokinetic features in patients with a severe outcome of schizophrenia, resistant to antipsychotic therapy. Science and Innovations. 2023;(7):78-83. (In Russ.) https://doi.org/10.29235/1818-9857-2023-07-78-83
Views: 169
Email this article 